Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Role of Glypicans in Cancer Progression and Therapy.

Literature DB >> 32623934

The Role of Glypicans in Cancer Progression and Therapy.

Nan Li¹, Madeline R Spetz¹, Mitchell Ho¹.

Abstract

Glypicans are a family of heparan sulfate proteoglycans that are attached to the cell membrane via a glycosylphosphatidylinositol anchor. Glypicans interact with multiple ligands, including morphogens, growth factors, chemokines, ligands, receptors, and components of the extracellular matrix through their heparan sulfate chains and core protein. Therefore, glypicans can function as coreceptors to regulate cell proliferation, cell motility, and morphogenesis. In addition, some glypicans are abnormally expressed in cancers, possibly involved in tumorigenesis, and have the potential to be cancer-specific biomarkers. Here, we provide a brief review focusing on the expression of glypicans in various cancers and their potential to be targets for cancer therapy.

Entities: Chemical Disease

Keywords: biomarker; cancer; extracellular matrix; glycosaminoglycan; glypican; heparan sulfate proteoglycan; immunostaining

Mesh：

Substances：
Glypicans

Year: 2020 PMID： 32623934 PMCID： PMC7711243 DOI： 10.1369/0022155420933709

Source DB: PubMed Journal: J Histochem Cytochem ISSN： 0022-1554 Impact factor: 2.479

189 in total

1. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.

Authors: Ernest K Amankwah; Hui-Yi Lin; Jonathan P Tyrer; Kate Lawrenson; Joe Dennis; Ganna Chornokur; Katja K H Aben; Hoda Anton-Culver; Natalia Antonenkova; Fiona Bruinsma; Elisa V Bandera; Yukie T Bean; Matthias W Beckmann; Maria Bisogna; Line Bjorge; Natalia Bogdanova; Louise A Brinton; Angela Brooks-Wilson; Clareann H Bunker; Ralf Butzow; Ian G Campbell; Karen Carty; Zhihua Chen; Y Ann Chen; Jenny Chang-Claude; Linda S Cook; Daniel W Cramer; Julie M Cunningham; Cezary Cybulski; Agnieszka Dansonka-Mieszkowska; Andreas du Bois; Evelyn Despierre; Ed Dicks; Jennifer A Doherty; Thilo Dörk; Matthias Dürst; Douglas F Easton; Diana M Eccles; Robert P Edwards; Arif B Ekici; Peter A Fasching; Brooke L Fridley; Yu-Tang Gao; Aleksandra Gentry-Maharaj; Graham G Giles; Rosalind Glasspool; Marc T Goodman; Jacek Gronwald; Patricia Harrington; Philipp Harter; Hanis N Hasmad; Alexander Hein; Florian Heitz; Michelle A T Hildebrandt; Peter Hillemanns; Claus K Hogdall; Estrid Hogdall; Satoyo Hosono; Edwin S Iversen; Anna Jakubowska; Allan Jensen; Bu-Tian Ji; Beth Y Karlan; Heather Jim; Melissa Kellar; Lambertus A Kiemeney; Camilla Krakstad; Susanne K Kjaer; Jolanta Kupryjanczyk; Diether Lambrechts; Sandrina Lambrechts; Nhu D Le; Alice W Lee; Shashi Lele; Arto Leminen; Jenny Lester; Douglas A Levine; Dong Liang; Boon Kiong Lim; Jolanta Lissowska; Karen Lu; Jan Lubinski; Lene Lundvall; Leon F A G Massuger; Keitaro Matsuo; Valerie McGuire; John R McLaughlin; Ian McNeish; Usha Menon; Roger L Milne; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Heli Nevanlinna; Ursula Eilber; Kunle Odunsi; Sara H Olson; Irene Orlow; Sandra Orsulic; Rachel Palmieri Weber; James Paul; Celeste L Pearce; Tanja Pejovic; Liisa M Pelttari; Jennifer Permuth-Wey; Malcolm C Pike; Elizabeth M Poole; Harvey A Risch; Barry Rosen; Mary Anne Rossing; Joseph H Rothstein; Anja Rudolph; Ingo B Runnebaum; Iwona K Rzepecka; Helga B Salvesen; Eva Schernhammer; Ira Schwaab; Xiao-Ou Shu; Yurii B Shvetsov; Nadeem Siddiqui; Weiva Sieh; Honglin Song; Melissa C Southey; Beata Spiewankiewicz; Lara Sucheston-Campbell; Soo-Hwang Teo; Kathryn L Terry; Pamela J Thompson; Lotte Thomsen; Ingvild L Tangen; Shelley S Tworoger; Anne M van Altena; Robert A Vierkant; Ignace Vergote; Christine S Walsh; Shan Wang-Gohrke; Nicolas Wentzensen; Alice S Whittemore; Kristine G Wicklund; Lynne R Wilkens; Anna H Wu; Xifeng Wu; Yin-Ling Woo; Hannah Yang; Wei Zheng; Argyrios Ziogas; Linda E Kelemen; Andrew Berchuck; Joellen M Schildkraut; Susan J Ramus; Ellen L Goode; Alvaro N A Monteiro; Simon A Gayther; Steven A Narod; Paul D P Pharoah; Thomas A Sellers; Catherine M Phelan
Journal: Genet Epidemiol Date: 2015-09-24 Impact factor: 2.135

2. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2.

Authors: H H Song; W Shi; J Filmus
Journal: J Biol Chem Date: 1997-03-21 Impact factor: 5.157

3. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.

Authors: Zeyan Pan; Shengmeng Di; Bizhi Shi; Hua Jiang; Zhimin Shi; Ying Liu; Yi Wang; Hong Luo; Min Yu; Xiuqi Wu; Zonghai Li
Journal: Cancer Immunol Immunother Date: 2018-08-04 Impact factor: 6.968

4. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.

Authors: Daniel Baumhoer; Luigi Tornillo; Sylvia Stadlmann; Massimo Roncalli; Eva Karamitopoulou Diamantis; Luigi M Terracciano
Journal: Am J Clin Pathol Date: 2008-06 Impact factor: 2.493

5. Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model.

Authors: Sandra Jalvy-Delvaille; Marion Maurel; Vanessa Majo; Nathalie Pierre; Sandrine Chabas; Chantal Combe; Jean Rosenbaum; Francis Sagliocco; Christophe F Grosset
Journal: Nucleic Acids Res Date: 2011-10-18 Impact factor: 16.971

Review 6. Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.

Authors: Arvindhan Nagarajan; Parmanand Malvi; Narendra Wajapeyee
Journal: Front Endocrinol (Lausanne) Date: 2018-08-24 Impact factor: 5.555

Review 7. Glypicans.

Authors: Jorge Filmus; Mariana Capurro; Jonathan Rast
Journal: Genome Biol Date: 2008-05-22 Impact factor: 13.583

8. The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer.

Authors: Yan Li; Liyun Miao; Hourong Cai; Jingjing Ding; Yonglong Xiao; Jun Yang; Deping Zhang
Journal: Oncol Lett Date: 2013-10-11 Impact factor: 2.967

9. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.

Authors: Takahiko Nishigaki; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomoharu Ohkawara; Hisashi Hara; Takahito Sugase; Toru Otsuru; Yurina Saito; Shigehiro Tsujii; Taisei Nomura; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Kiyokazu Nakajima; Hidetoshi Eguchi; Makoto Yamasaki; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal: Br J Cancer Date: 2020-03-10 Impact factor: 7.640

10. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab.

Authors: Daiki Kato; Tomonori Yaguchi; Takashi Iwata; Yuki Katoh; Kenji Morii; Kinya Tsubota; Yoshiaki Takise; Masaki Tamiya; Haruhiko Kamada; Hiroki Akiba; Kouhei Tsumoto; Satoshi Serada; Tetsuji Naka; Ryohei Nishimura; Takayuki Nakagawa; Yutaka Kawakami
Journal: Elife Date: 2020-03-31 Impact factor: 8.140

13 in total

1. A highly sensitive strategy for glypican-3 detection based on aptamer/gold carbon dots/magnetic graphene oxide nanosheets as fluorescent biosensor.

Authors: Guiyin Li; Wei Chen; Danhong Mi; Bo Wang; HaiMei Li; Guangxiong Wu; Ping Ding; Jintao Liang; Zhide Zhou
Journal: Anal Bioanal Chem Date: 2022-07-05 Impact factor: 4.478

2. Identifying Molecular Subtypes and 6-Gene Prognostic Signature Based on Hypoxia for Optimizing Targeted Therapies in Non-Small Cell Lung Cancer.

Authors: Jingrong Lin; Shujiao Chen; Linling Xiao; Ziyan Wang; Yanqing Lin; Shungui Xu
Journal: Int J Gen Med Date: 2022-04-26

The Role of Glypicans in Cancer Progression and Therapy.

1. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.

2. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2.

3. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.

4. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.

5. Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model.

Review 6. Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.

Review 7. Glypicans.

8. The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer.

9. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.

10. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab.

1. A highly sensitive strategy for glypican-3 detection based on aptamer/gold carbon dots/magnetic graphene oxide nanosheets as fluorescent biosensor.

2. Identifying Molecular Subtypes and 6-Gene Prognostic Signature Based on Hypoxia for Optimizing Targeted Therapies in Non-Small Cell Lung Cancer.

Review 3. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Review 4. Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management.

5. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.

Review 6. A Bittersweet Computational Journey among Glycosaminoglycans.

7. HA and HS Changes in Endothelial Inflammatory Activation.

Review 8. Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment.

9. Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.

10. Glypican-1 Overexpression in Different Types of Breast Cancers.